Skip to main content

Advertisement

SpringerLink
Log in

Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma is a rare extranodal lymphoma with a 5-year survival rate of 80–95 %. There is no standard treatment strategy for pulmonary MALT lymphoma. In the present study, we performed a retrospective evaluation of systemic rituximab monotherapy (375 mg m−2 day−1, 4–8 cycles) as first-line treatment in patients with pulmonary MALT lymphoma. Of the eight patients enrolled, five achieved complete response, one achieved partial response, and two showed stable disease. Median progression-free survival was 66.0 months (range 9.7–87.2 months). Treatment was well tolerated and all patients were alive during the median follow-up period of 64.0 months. Rituximab monotherapy was efficacious in patients with pulmonary MALT lymphoma, demonstrating long-term disease stabilization and symptom reduction. Larger prospective studies are warranted to further assess the efficacy of rituximab monotherapy. In conclusion, rituximab monotherapy may be considered for first-line therapy in patients with pulmonary MALT lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer. 1983;52(8):1410–6.

    Article  CAS  PubMed  Google Scholar 

  2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2008.

    Google Scholar 

  3. Nicholson AG, Wotherspoon AC, Diss TC, Hansell DM, Du Bois R, Sheppard MN, et al. Reactive pulmonary lymphoid disorders. Histopathology. 1995;26(5):405–12.

    Article  CAS  PubMed  Google Scholar 

  4. Adam P, Czapiewski P, Colak S, Kosmidis P, Tousseyn T, Sagaert X, et al. Prevalence of Achromobacter xylosoxidans in pulmonary mucosa-associated lymphoid tissue lymphoma in different regions of Europe. Br J Haematol. 2014;164(6):804–10.

    Article  CAS  PubMed  Google Scholar 

  5. Ahmed S, Kussick SJ, Siddiqui AK, Bhuiya TA, Khan A, Sarewitz S, et al. Bronchial-associated lymphoid tissue lymphoma: a clinical study of a rare disease. Eur J Cancer. 2004;40(9):1320–6.

    Article  PubMed  Google Scholar 

  6. Graham BB, Mathisen DJ, Mark EJ, Takvorian RW. Primary pulmonary lymphoma. Ann Thorac Surg. 2005;80(4):1248–53.

    Article  PubMed  Google Scholar 

  7. Saltzstein SL. Pulmonary malignant lymphomas and pseudolymphomas: classification, therapy, and prognosis. Cancer. 1963;16:928–55.

    Article  CAS  PubMed  Google Scholar 

  8. Koss MN, Hochholzer L, Nichols PW, Wehunt WD, Lazarus AA. Primary non-Hodgkin’s lymphoma and pseudolymphoma of lung: a study of 161 patients. Hum Pathol. 1983;14(12):1024–38.

    Article  CAS  PubMed  Google Scholar 

  9. Addis BJ, Hyjek E, Isaacson PG. Primary pulmonary lymphoma: a re-appraisal of its histogenesis and its relationship to pseudolymphoma and lymphoid interstitial pneumonia. Histopathology. 1988;13(1):1–17.

    Article  CAS  PubMed  Google Scholar 

  10. Kurtin PJ, Myers JL, Adlakha H, Strickler JG, Lohse C, Pankratz VS, et al. Pathologic and clinical features of primary pulmonary extranodal marginal zone B-cell lymphoma of MALT type. Am J Surg Pathol. 2001;25(8):997–1008.

    Article  CAS  PubMed  Google Scholar 

  11. Maloney DG. Mechanism of action of rituximab. Anticancer Drugs. 2001;12(Suppl 2):S1–4.

    CAS  PubMed  Google Scholar 

  12. Grillo-Lopez AL. Monoclonal antibody therapy for B-cell lymphoma. Int J Hematol. 2002;76(5):385–93.

    Article  CAS  PubMed  Google Scholar 

  13. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42.

    Article  CAS  PubMed  Google Scholar 

  14. Raderer M, Jager G, Brugger S, Puspok A, Fiebiger W, Drach J, et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology. 2003;65(4):306–10.

    Article  CAS  PubMed  Google Scholar 

  15. Conconi A, Martinelli G, Thieblemont C, Ferreri AJ, Devizzi L, Peccatori F, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102(8):2741–5.

    Article  CAS  PubMed  Google Scholar 

  16. Seker M, Bilici A, Ustaalioglu BO, Salman T, Sonmez B, Canpolat NA, et al. Extended rituximab schedules may result in increased efficacy in pulmonary malt lymphoma. Leuk Res. 2009;33(9):e154–6.

    Article  CAS  PubMed  Google Scholar 

  17. Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer J Clin. 2005;55(6):368–76.

    Article  PubMed  Google Scholar 

  18. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.

    CAS  PubMed  Google Scholar 

  19. Zucca E, Conconi A, Laszlo D, Lopez-Guillermo A, Bouabdallah R, Coiffier B, et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J Clin Oncol. 2013;31(5):565–72.

    Article  CAS  PubMed  Google Scholar 

  20. Ahmed S, Siddiqui AK, Rai KR. Low-grade B-cell bronchial associated lymphoid tissue (BALT) lymphoma. Cancer Invest. 2002;20(7–8):1059–68.

    Article  PubMed  Google Scholar 

  21. Cordier JF, Chailleux E, Lauque D, Reynaud-Gaubert M, Dietemann-Molard A, Dalphin JC, et al. Primary pulmonary lymphomas. A clinical study of 70 cases in nonimmunocompromised patients. Chest. 1993;103(1):201–8.

    Article  CAS  PubMed  Google Scholar 

  22. Ferraro P, Trastek VF, Adlakha H, Deschamps C, Allen MS, Pairolero PC. Primary non-Hodgkin’s lymphoma of the lung. Ann Thorac Surg. 2000;69(4):993–7.

    Article  CAS  PubMed  Google Scholar 

  23. Li G, Hansmann ML, Zwingers T, Lennert K. Primary lymphomas of the lung: morphological, immunohistochemical and clinical features. Histopathology. 1990;16(6):519–31.

    Article  CAS  PubMed  Google Scholar 

  24. Herbert A, Wright DH, Isaacson PG, Smith JL. Primary malignant lymphoma of the lung: histopathologic and immunologic evaluation of nine cases. Hum Pathol. 1984;15(5):415–22.

    Article  CAS  PubMed  Google Scholar 

  25. Zucca E, Bertoni F, Roggero E, Cavalli F. The gastric marginal zone B-cell lymphoma of MALT type. Blood. 2000;96(2):410–9.

    CAS  PubMed  Google Scholar 

  26. Cavalli F, Isaacson PG, Gascoyne RD, Zucca E. MALT lymphomas. Hematology Am Soc Hematol Educ Program. 2001;2001:241–58.

    Article  Google Scholar 

  27. Zucca E, Conconi A, Pedrinis E, Cortelazzo S, Motta T, Gospodarowicz MK, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003;101(7):2489–95.

    Article  CAS  PubMed  Google Scholar 

  28. Hitchcock S, Ng AK, Fisher DC, Silver B, Bernardo MP, Dorfman DM, et al. Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2002;52(4):1058–66.

    Article  PubMed  Google Scholar 

  29. Thieblemont C, Bastion Y, Berger F, Rieux C, Salles G, Dumontet C, et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol. 1997;15(4):1624–30.

    CAS  PubMed  Google Scholar 

  30. Thieblemont C, Berger F, Dumontet C, Moullet I, Bouafia F, Felman P, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood. 2000;95(3):802–6.

    CAS  PubMed  Google Scholar 

  31. Zinzani PL, Magagnoli M, Galieni P, Martelli M, Poletti V, Zaja F, et al. Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol. 1999;17(4):1254.

    CAS  PubMed  Google Scholar 

  32. Pinotti G, Zucca E, Roggero E, Pascarella A, Bertoni F, Savio A, et al. Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. Leuk Lymphoma. 1997;26(5–6):527–37.

    CAS  PubMed  Google Scholar 

  33. Hammel P, Haioun C, Chaumette MT, Gaulard P, Divine M, Reyes F, et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol. 1995;13(10):2524–9.

    CAS  PubMed  Google Scholar 

  34. Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol. 1998;16(5):1916–21.

    CAS  PubMed  Google Scholar 

  35. Tsang RW, Gospodarowicz MK, Pintilie M, Bezjak A, Wells W, Hodgson DC, et al. Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys. 2001;50(5):1258–64.

    Article  CAS  PubMed  Google Scholar 

  36. NCCN clinical practice guidelines in oncology. Non-Hodgkin’s lymphomas. http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf. Accessed version 3, 2014

  37. Zinzani PL, Pellegrini C, Gandolfi L, Casadei B, Derenzini E, Broccoli A, et al. Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. Hematol Oncol. 2013;31(4):183–8.

    Article  CAS  PubMed  Google Scholar 

  38. Imai H, Sunaga N, Kaira K, Kawashima O, Yanagitani N, Sato K, et al. Clinicopathological features of patients with bronchial-associated lymphoid tissue lymphoma. Intern Med. 2009;48(5):301–6.

    Article  PubMed  Google Scholar 

  39. Borie R, Wislez M, Thabut G, Antoine M, Rabbat A, Couderc LJ, et al. Clinical characteristics and prognostic factors of pulmonary MALT lymphoma. Eur Respir J. 2009;34(6):1408–16.

    Article  CAS  PubMed  Google Scholar 

  40. Bilici A, Seker M, Ustaalioglu BB, Canpolat N, Salepci T, Gumus M. Pulmonary BALT lymphoma successfully treated with eight cycles weekly rituximab: report of first case and F-18 FDG PET/CT images. J Korean Med Sci. 2011;26(4):574–6.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Berinstein NLG-LA, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol. 1998;9(9):995–1001.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We wish to thank Ms. Mutsumi Yamazaki, Mr. Taiki Miyauchi, Drs. Akira Ono, Tetsuhiko Taira, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Yoshio Tomizawa, and Masahiro Endo for their assistance in preparing this manuscript.

Conflict of interest

The authors do not have any financial or personal conflicts of interest to declare that could influence the work herein.

Author information

Authors and Affiliations

  1. Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-chou, Suntou-gun, Shizuoka, 411-8777, Japan

    Ikue Okamura, Kazuto Ogura & Takashi Ikeda

  2. Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-chou, Suntou-gun, Shizuoka, 411-8777, Japan

    Hisao Imai & Toshiaki Takahashi

  3. Clinical Trial Coordination Office, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-chou, Suntou-gun, Shizuoka, 411-8777, Japan

    Keita Mori

  4. Department of Hematology, National Hospital Organization Nishigunma Hospital, 2854 Kanai, Shibukawa, Gunma, 377-8511, Japan

    Atsushi Isoda & Morio Matsumoto

  5. Department of Respiratory Medicine, National Hospital Organization Nishigunma Hospital, 2854 Kanai, Shibukawa, Gunma, 377-8511, Japan

    Ryusei Saito

  6. Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minamiku, Hiroshima, 734-8553, Japan

    Keichiro Mihara

Authors
  1. Ikue Okamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hisao Imai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keita Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazuto Ogura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Atsushi Isoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Keichiro Mihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Morio Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ryusei Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Toshiaki Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takashi Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hisao Imai.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Okamura, I., Imai, H., Mori, K. et al. Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma. Int J Hematol 101, 46–51 (2015). https://doi.org/10.1007/s12185-014-1694-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-014-1694-8

Keywords

Search

Navigation